BHCM
DNTH icon

Brevan Howard Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

Brevan Howard Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.77M Sell
18,205
-1,225
-6% -$107K 0.01% 775
2026
Q1 		$1.63M Sell
19,430
-32,270
-62% -$1.87M 0.01% 655
2025
Q4 		$2.14M Buy
51,700
+39,770
+333% +$1.54M 0.02% 467
2025
Q3 		$469K Buy
+11,930
New +$305K ﹤0.01% 1324
2024
Q2 		– Sell
-12,253
Closed -$368K – 1128
2024
Q1 		$368K Buy
+12,253
New +$266K ﹤0.01% 572

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Brevan Howard Capital Management's DNTH Position: Q2 2026 in Review

Brevan Howard Capital Management reduced its Dianthus Therapeutics (DNTH) stake by 6.3% in Q2 2026, selling an estimated $107K and leaving 18,205 shares worth $1.77M. The position accounts for 0.01% of the portfolio, ranked #775.

Brevan Howard Capital Management first reported a position in DNTH in Q1 2024 and has held it in 5 quarters since. The position peaked at $2.14M in Q4 2025. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Brevan Howard Capital Management held 18,205 shares of Dianthus Therapeutics worth $1.77M as of Q2 2026.
  • Brevan Howard Capital Management sold 1,225 Dianthus Therapeutics shares in Q2 2026, an estimated $107K.
  • Dianthus Therapeutics made up 0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #775 holding.
  • Brevan Howard Capital Management first reported a position in Dianthus Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • Brevan Howard Capital Management's Dianthus Therapeutics position peaked at $2.14M in Q4 2025.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.